期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.757323
关键词
lung cancer; metabolism; metabolic inhibitors; glycolysis (Warburg effect); oxidative phosphorylation
类别
资金
- University of Texas SPORE in Lung Cancer [P5-CA070907]
- NIH/NCI [T32 CA009666, R01-CA207295, U01-CA213273]
- ASCO Young Investigator Award
- IALSC ILCF Fellowship
- Khalifa Bin Zayed Al Nahyan Foundation
- Andrew Sabin Family Fellowship
- Abell Hangar Foundation
- LUNGevity Foundation Career Development Award
- Rexanna Foundation for Fighting Lung Cancer
Metabolic reprogramming is a key feature of cancer initiation, progression, and relapse, with unique shifts in metabolism playing an important role in targeting cancer treatment. Research on lung cancer metabolism has been relatively limited, but recent evidence suggests that lung cancers have their own unique metabolic preferences.
Metabolic reprogramming is a hallmark of cancer initiation, progression, and relapse. From the initial observation that cancer cells preferentially ferment glucose to lactate, termed the Warburg effect, to emerging evidence indicating that metabolic heterogeneity and mitochondrial metabolism are also important for tumor growth, the complex mechanisms driving cancer metabolism remain vastly unknown. These unique shifts in metabolism must be further investigated in order to identify unique therapeutic targets for individuals afflicted by this aggressive disease. Although novel therapies have been developed to target metabolic vulnerabilities in a variety of cancer models, only limited efficacy has been achieved. In particular, lung cancer metabolism has remained relatively understudied and underutilized for the advancement of therapeutic strategies, however recent evidence suggests that lung cancers have unique metabolic preferences of their own. This review aims to provide an overview of essential metabolic mechanisms and potential therapeutic agents in order to increase evidence of targeted metabolic inhibition for the treatment of lung cancer, where novel therapeutics are desperately needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据